We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VLRS:NYSEControladora Vuela Compania de Aviacion, S.A.B. de C.V. Analysis

Data as of 2026-09-15 - not real-time

$6.42

Latest Price

9/10Risk

Risk Level: High

Executive Summary

At $6.42, Controladora Vuela Compañía de Aviación, S.A.B. de C.V. shows a bearish moving-average alignment, with shorter averages beneath longer ones. The last 30 days have lost 18.0%. RSI sits at 34.1, which reads as approaching oversold, and MACD momentum is bullish. Recent trading has carved out support near $6.29 and resistance around $7.85.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 47.4% above today's level. Revenue is growing at 23.9% on a -5.7% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 37.5%, a beta of 1.90 and a maximum drawdown of 42.1%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 91 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 3 out of 10.

Top Market Events

MEXICO CITY, May 06, 2026 GLOBE NEWSWIRE -- Controladora Vuela Compañía de Aviación, S.MEXICO CITY, Aug. 05, 2026 GLOBE NEWSWIRE -- Controladora Vuela Compañía de Aviación, S.A.B. de C.V. NYSE: VLRS and...MEXICO CITY, April 27, 2026 GLOBE NEWSWIRE -- Controladora Vuela Compañía de Aviación, S.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 8.06
  • MACD momentum is positive

Medium Term

1–3 years
Cautious
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 8.06
  • Analyst targets imply +47.4% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Negative profit margin of -5.7%
  • Analyst targets imply +47.4% versus the current price
  • Negative return on equity of -116.8%

Key Metrics & Analysis

Financial Health

Revenue Growth23.90%
Profit Margin-5.70%
P/E Ratio-32.3
ROE-116.83%
ROA0.12%
Debt/Equity5717.21
P/B Ratio10.9
Op. Cash Flow$979.9M
Free Cash Flow$429.9M
Industry P/E27.6

Technical Analysis

TrendBearish
RSI34.1
Support$6.29
Resistance$7.85
MA 20$6.82
MA 50$7.56
MA 200$8.06
MACDBullish
VolumeDecreasing
Fear & Greed Index90.89

Valuation

Fair Value$94.07
Target Price$9.46
Upside/Downside47.38%
GradeFair
TypeGrowth

Risk Assessment

Beta1.90
Volatility37.54%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.